Genomics and Population Health Action Collaborative
The goal of the Evidence Working Group was to understand the type and level of evidence required to implement genomic applications at the public health level. This work focused primarily on two case studies – mutations in BRCA1 and BRCA2 that cause hereditary breast and ovarian cancer and mutations that cause Lynch syndrome.
|Ned Calonge, M.D.
President and CEO
The Colorado Trust
Group members prepared a white paper, Building the Evidence Base for Genomics in Public Health, which details the process of horizon scanning and how evidence assessment consortia evaluated genetic tests for BRCA1, BRCA2, and Lynch syndrome.
The Genomics and Population Health Action Collaborative, is an ad hoc activity under the auspices of the Roundtable on Genomics and Precision Health at the National Academies of Sciences, Engineering, and Medicine (the National Academies). The products of the action collaborative do not necessarily represent the views of any one organization, the Roundtable, or the National Academies and have not been subjected to the review procedures of, nor are they a report or product of, the National Academies.
For more information about the Genomics and Population Health Action Collaborative, please click here.